In patients with a genetic predisposition to breast cancer, particularly those with TP53 and BRCA1/2 germline mutations, BIA-ALCL prevalence appears to be higher, and the time to onset seems to be shorter compared to the general population [8,9]. The gene discussed is TP53; the disease is breast carcinoma.